Pomerantz LLP is investigating Johnson & Johnson for potential securities fraud following the company's Q3 2026 report, which showed net earnings of $210 million due to large charges from talc litigation settlements. The MedTech segment's revenue growth was only 2.5%, impacted by pricing issues in China and geopolitical tensions in the Middle East. J&J's stock dropped 5.73% after the announcement. The investigation could lead to a class action lawsuit if wrongdoing is found.
Johnson & Johnson shares trade at USD 268.75 on Pluang, showing a 0.92% gain as of Oct 28, 2026 05:02 WIB, despite the recent 5.73% drop reported after their Q3 earnings announcement. The stock's market cap stands at $641.07 billion, with a dividend yield of 2.01%, and a typical hold time of 130 days on the platform. This steady trading contrasts with the legal scrutiny highlighted in the news.
Medtronic increased its quarterly dividend to $0.72 per share, marking a 1.4% raise and extending its dividend increase streak to 49 years. While this steady growth ensures a reliable 2.95% yield, it trails behind faster-growing peers like Abbott and...
Johnson & Johnson and Procter & Gamble are highlighted as two safe S&P 500 dividend stocks ideal for retirees seeking reliable income. Johnson & Johnson has raised its dividend for 64 consecutive years, supported by strong free cash flow and diverse ...
New Phase 3 PROTEUS substudy results show that adding apalutamide plus androgen deprivation therapy (ADT) before and after surgery reduces the risk of prostate cancer recurrence or death by 62% compared to surgery alone in high-risk localized or loca...
The CHMP of the European Medicines Agency has recommended approval for Johnson & Johnson's TALVEY (talquetamab) combined with daratumumab, with or without pomalidomide, for treating adults with relapsed or refractory multiple myeloma who have had at ...
The European Medicines Agency's CHMP has recommended approving Johnson & Johnson's TALVEY® (talquetamab) combined with daratumumab for treating relapsed or refractory multiple myeloma earlier in the treatment process, starting from the second line. T...
